Clarke Acquires Becker Microbial Products and the AquaBac Family of Products

ST. CHARLES, Ill. – Clarke, a provider of public health vector management solutions, has completed its acquisition of Becker Microbial Products and its AquaBac larvicide line, including ownership of Becker’s proprietary Bacillus thuringiensis subspecies israelensis (Bti) strain. The transaction marks Clarke’s largest acquisition in its nearly 80-year history. Financial terms were not disclosed. The move expands Clarke’s larvicide portfolio, which also includes the Spinosad-based Natular® line, both environmentally friendly and OMRI Listed® for use in and around organic areas.

“Clarke’s Natular and AquaBac go hand in hand, providing complementary larval control designed to reduce the risk of resistance and keep our communities livable, safe and comfortable,” said Allen Gent, Clarke’s president and CEO. “By adding AquaBac to our family of products, we can offer customers more options for effective rotation strategies, backed by full-scale product stewardship, training and operational support.”

Clarke will also acquire the technical registration for the Bti strain that powers AquaBac formulations. “This trusted, proven Bti active ingredient strengthens our portfolio and meets evolving customer needs across multiple markets and environments,” said Laetitia Leroy, Clarke’s director of research, development and engineering.

PMPs can learn more about AquaBac and Clarke’s larvicide portfolio at www.clarke.com.